Anticipated acquisition by Bupa Insurance Limited of Civil Service Healthcare Society Limited Decision on relevant merger situation and substantial lessening of competition ME/6887-20 The CMA’s decision on reference under section 33(1) of the Enterprise Act 2002 given on 24 September 2020. Full text of the decision published on 8 October 2020. Please note that [] indicates figures or text which have been deleted or replaced in ranges at the request of the parties or third parties for reasons of commercial confidentiality. SUMMARY 1. Bupa Insurance Limited (Bupa) has agreed to acquire Civil Service Healthcare Society Limited (CSH) (the Merger). Bupa and CSH are together referred to as the Parties and, for statements relating to the future, the Merged Entity. 2. The Competition and Markets Authority (CMA) believes that it is or may be the case that each of Bupa and CSH is an enterprise; that these enterprises will cease to be distinct as a result of the Merger; and that the share of supply test is met. Accordingly, arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation. 3. The Parties overlap in the supply of personal (ie, non-corporate) private medical insurance (PMI) in the UK. Bupa is also active in the SME PMI, large corporate PMI and healthcare trusts segments, where CSH is not present. The CMA has therefore assessed the impact of the Merger in the supply of personal PMI in the UK. 4. The CMA believes that while Bupa is the largest supplier of personal PMI in the UK with a [30-40]% share of the market, the increment from the Merger will be small at approximately [0-5]%. The CMA believes that the Parties do 1 not compete closely with each other, as they rely on different customer acquisition channels and focus on different customer bases. The CMA also believes that the Merged Entity would face sufficient constraint from alternative suppliers, particularly AXA, Aviva and Vitality. 5. The CMA believes that these constraints, taken together, are sufficient to ensure that the Merger does not give rise to a realistic prospect of a substantial lessening of competition (SLC) as a result of horizontal unilateral effects in relation to the supply of personal PMI in the UK. 6. The Merger will therefore not be referred under section 33(1) of the Enterprise Act 2002 (the Act). ASSESSMENT Parties 7. Bupa is a private company registered in the UK that provides medical cover to 2.7 million customers worldwide.1 8. Bupa is a wholly owned subsidiary of The British United Provident Association Limited (the Bupa Group), a global health and care company headquartered in the UK. The Bupa Group runs care homes, retirement and care villages, primary care, diagnostics and wellness centres and hospitals. 9. The turnover of Bupa in the financial year ending 31 December 2019 was £2,329 million worldwide and £2,148 million in the UK. The turnover of Bupa Group in the financial year ending 31 December 2019 was £12,316 million worldwide and £3,099 million in the UK. 10. CSH is a UK-based Friendly Society that provides health insurance to the UK consumer market. As a friendly society, it has no shareholders but has members who are its policyholders from time to time. 11. CSH offered health insurance only to members of the armed forces, civil services and not-for-profit organisations until 2019. However, it now offers insurance services to individuals regardless of their profession. 12. As at 30 September 2019, CSH had 12,438 policies covering 19,485 lives, including [] policies for members based outside of the UK. CSH's members obtain PMI directly from CSH. However, a small number of these individuals are introduced to CSH through affinity schemes recommended by 1 Merger Notice, 4 August 2020, paragraphs 2.4 and 3.2. 2 their employer. CSH has a small number of these affinity schemes in place with employers such as schools or government bodies (for example, [] and []). 13. CSH achieves all of its revenues in the UK and its turnover in the financial year ending 31 December 2019 was £26 million.2 Transaction 14. Bupa agreed to acquire all of CSH's undertaking by means of a proposed transfer of engagements in accordance with and pursuant to section 86 of, and Schedule 15 to, the Friendly Societies Act 1992. 15. On 30 July 2020, the Parties entered into a Framework Agreement which sets out the terms of the transfer, including the conditions precedent, and annexes the agreed form instrument of transfer (Instrument of Transfer). 16. The Instrument of Transfer will be entered into once all conditions precedent have been satisfied, including merger control clearance by the CMA and the Channel Islands Competition and Regulatory Authorities (CIRCA), approval by a Special Resolution of the members of CSH and confirmation of the transfer by the Prudential Regulation Authority (PRA). The Financial Conduct Authority (FCA) will then issue the registration certificate which will complete the Merger. 17. Subject to regulatory approval, the Parties are anticipating completion of the Merger on 30 November 2020.i 18. []. 19. On transferring its engagements to Bupa, CSH will automatically be dissolved by operation of law. Its members will become customers of Bupa but will no longer have any membership rights. Rationale for the Transaction 20. For CSH, the stated rationale for the Merger is that membership numbers have fallen over the years, operating costs have been cut as far as possible and attempts to expand CSH’s member base have been unsuccessful. Accordingly, CSH has had to consider future strategic options including the 3 merger with another PMI supplier in order to remain a viable business. 2 Merger Notice, 4 August 2020, paragraph 6.3. 3 Merger Notice, 4 August 2020, paragraph 2.31. 3 21. For Bupa, the stated rationale is that the Merger is []. Furthermore, Bupa submitted that CSH’s and Bupa’s values align, and that the Merger would enable Bupa to enhance CSH’s product range and ensure continuation of cover and a long-term solution for CSH members.4 Jurisdiction 22. Each of BUPA and CSH is an enterprise for the purposes of the Act. As a result of the Merger, these enterprises will cease to be distinct. 23. The Parties overlap in the supply of personal PMI in the UK, with a combined share of supply exceeding 25% and an increment of approximately [0-5]% (see Table 1 below). The CMA therefore believes that the share of supply test in section 23 of the Act is met. 24. The CMA therefore believes that it is or may be the case that arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation. 25. The initial period for consideration of the Merger under section 34ZA(3) of the Act started on 20 August 2020 and the statutory 40 working day deadline for a decision is therefore 15 October 2020. Counterfactual 26. The CMA assesses a merger’s impact relative to the situation that would prevail absent the merger (ie the counterfactual). For anticipated mergers, the CMA generally adopts the prevailing conditions of competition as the counterfactual against which to assess the impact of the merger. However, the CMA will assess the merger against an alternative counterfactual where, based on the evidence available to it, it believes that, in the absence of the merger, the prospect of these conditions continuing is not realistic, or there is a realistic prospect of a counterfactual that is more competitive than these conditions.5 27. The Parties submitted that the pre-existing parameters of competition are the correct conditions on which to assess the Merger.6 The CMA has not seen any evidence supporting a different counterfactual and third parties 4 Merger Notice, 4 August 2020, paragraph 2.33. 5 Merger Assessment Guidelines (OFT1254/CC2), September 2010, from paragraph 4.3.5. The Merger Assessment Guidelines have been adopted by the CMA (see Mergers: Guidance on the CMA’s jurisdiction and procedure (CMA2), January 2014, Annex D). 6 Merger Notice, 4 August 2020, paragraph 11.1. 4 have not put forward arguments in this respect. Therefore, the CMA believes the prevailing conditions of competition to be the relevant counterfactual. Frame of reference 28. Market definition provides a framework for assessing the competitive effects of a merger and involves an element of judgement. The boundaries of the market do not determine the outcome of the analysis of the competitive effects of the merger, as it is recognised that there can be constraints on merging parties from outside the relevant market, segmentation within the relevant market, or other ways in which some constraints are more important than others. The CMA will take these factors into account in its competitive assessment.7 29. The Parties overlap in the supply of personal (ie non-corporate)8 PMI in the UK. PMI is a form of non-life insurance which provides indemnity cover against the cost of medical treatment (for acute medical/surgical conditions) in private hospitals or clinics. Bupa is also active in the SME9 PMI, large corporate10 PMI and healthcare trusts11 segments, where CSH is not present.12 Product scope 30. The Parties submitted that the appropriate candidate product frame of reference is the PMI market, without further segmentation between customer groups. The Parties also noted that this is consistent with the 13 14 AXA/Simplyhealth decision. 7 Merger Assessment Guidelines, paragraph 5.2.2. 8 The PMI market can be segmented by customer group: the personal segment includes private individuals who buy PMI cover for themselves and family members; the corporate segment includes companies who buy PMI for their employees.